These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28143781)

  • 1. Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma.
    Trousil S; Chen S; Mu C; Shaw FM; Yao Z; Ran Y; Shakuntala T; Merghoub T; Manstein D; Rosen N; Cantley LC; Zippin JH; Zheng B
    J Invest Dermatol; 2017 May; 137(5):1135-1143. PubMed ID: 28143781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.
    Wong DJ; Robert L; Atefi MS; Lassen A; Avarappatt G; Cerniglia M; Avramis E; Tsoi J; Foulad D; Graeber TG; Comin-Anduix B; Samatar A; Lo RS; Ribas A
    Mol Cancer; 2014 Aug; 13():194. PubMed ID: 25142146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.
    Yuan P; Ito K; Perez-Lorenzo R; Del Guzzo C; Lee JH; Shen CH; Bosenberg MW; McMahon M; Cantley LC; Zheng B
    Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18226-31. PubMed ID: 24145418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global view of the RAF-MEK-ERK module and its immediate downstream effectors.
    Santini CC; Longden J; Schoof EM; Simpson CD; Jeschke GR; Creixell P; Kim J; Wu X; Turk BE; Rosen N; Poulikakos PI; Linding R
    Sci Rep; 2019 Jul; 9(1):10865. PubMed ID: 31350469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma.
    Krepler C; Xiao M; Samanta M; Vultur A; Chen HY; Brafford P; Reyes-Uribe PI; Halloran M; Chen T; He X; Hristova D; Liu Q; Samatar AA; Davies MA; Nathanson KL; Fukunaga-Kalabis M; Herlyn M; Villanueva J
    Oncotarget; 2016 Nov; 7(44):71211-71222. PubMed ID: 27655717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss.
    He S; Zimmerman MW; Layden HM; Berezovskaya A; Etchin J; Martel MW; Thurston G; Jing CB; van Rooijen E; Kaufman CK; Rodig SJ; Zon LI; Patton EE; Mansour MR; Look AT
    Oncogene; 2021 Sep; 40(38):5718-5729. PubMed ID: 34331013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.
    Benito-Jardón L; Díaz-Martínez M; Arellano-Sánchez N; Vaquero-Morales P; Esparís-Ogando A; Teixidó J
    Cancer Res; 2019 May; 79(9):2244-2256. PubMed ID: 30833419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
    Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
    Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments.
    Mukherjee N; Almeida A; Partyka KA; Lu Y; Schwan JV; Lambert K; Rogers M; Robinson WA; Robinson SE; Applegate AJ; Amato CM; Luo Y; Fujita M; Norris DA; Shellman YG
    Oncotarget; 2016 Dec; 7(51):84594-84607. PubMed ID: 27829238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
    Woodfield SE; Zhang L; Scorsone KA; Liu Y; Zage PE
    BMC Cancer; 2016 Mar; 16():172. PubMed ID: 26925841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERK pathway inhibitors: how low should we go?
    Nissan MH; Rosen N; Solit DB
    Cancer Discov; 2013 Jul; 3(7):719-21. PubMed ID: 23847348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
    Whittaker SR; Theurillat JP; Van Allen E; Wagle N; Hsiao J; Cowley GS; Schadendorf D; Root DE; Garraway LA
    Cancer Discov; 2013 Mar; 3(3):350-62. PubMed ID: 23288408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma.
    Petrachi T; Romagnani A; Albini A; Longo C; Argenziano G; Grisendi G; Dominici M; Ciarrocchi A; Dallaglio K
    Oncotarget; 2017 Jan; 8(4):6914-6928. PubMed ID: 28036292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity of Phosphorylation Responses to Mitogen Activated Protein (MAP) Kinase Pathway Inhibitors in Melanoma Cells.
    Basken J; Stuart SA; Kavran AJ; Lee T; Ebmeier CC; Old WM; Ahn NG
    Mol Cell Proteomics; 2018 Apr; 17(4):550-564. PubMed ID: 29255136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway.
    Petti C; Vegetti C; Molla A; Bersani I; Cleris L; Mustard KJ; Formelli F; Hardie GD; Sensi M; Anichini A
    Melanoma Res; 2012 Oct; 22(5):341-50. PubMed ID: 22588166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition.
    Abecunas C; Whitehead CE; Ziemke EK; Baumann DG; Frankowski-McGregor CL; Sebolt-Leopold JS; Fallahi-Sichani M
    Cancer Res; 2023 Jan; 83(2):316-331. PubMed ID: 36409827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
    Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
    Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
    Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
    Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.